The global bone cancer treatment market size was estimated to be USD 1.32 billion in 2023 and is expected to reach USD 2.19 billion by 2034 with a CAGR of 4.72% during the forecast period 2024-2034. Increasing incidence of bone cancer, advancements in medical research and technology, innovations in treatment modalities, awareness and early detection, rising government initiatives and funding, and collaborations and partnerships will drive the market growth.
The market for bone cancer treatments is significantly driven by the disease's increasing global prevalence. The need for efficient treatment alternatives is projected to rise in tandem with the rise in the number of instances of bone cancer. Government programs that support the development of new drugs, clinical trials, and other forms of cancer research are vital. Increasing assistance can hasten the creation of novel treatments and enhance patient outcomes. For instance, in December 2023, the FDA approved Pfizer's Ibrance (palbociclib) to treat hormone-receptor-positive metastatic breast cancer that has spread to the bone.
By bone cancer type, the primary bone sarcoma segment accounted for the highest revenue-grossing segment in the global bone cancer treatment market in 2023 owing to the increasing incidence of primary bone sarcomas, advancements in targeted therapies specifically designed for this subtype, and a growing emphasis on personalized treatment approaches that address the unique characteristics of primary bone sarcomas. For instance, Novartis and Epizyme announced a collaboration in November 2023 to develop and market EZH2 inhibitors as a therapy for bone cancer. Additionally, the secondary bone cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of metastatic cancer cases, advancements in diagnostic techniques enabling early detection of secondary bone involvement, and the development of targeted therapies tailored to address the specific challenges associated with secondary bone cancer.
By treatment type, the surgery segment accounted for the highest revenue-grossing segment in the global bone cancer treatment market in 2023 owing to the increasing adoption of advanced surgical techniques, such as limb-salvage surgeries and minimally invasive procedures, which enhance treatment outcomes while preserving function. For instance, in December 2023, Eli Lilly presented preclinical results at the San Antonio Breast Cancer Symposium that indicated CYD2669 could play a role in reducing bone metastases in breast cancer. Additionally, the targeted therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing understanding of molecular pathways and genetic abnormalities associated with bone cancer, which has facilitated the development of more precise and effective targeted therapies.
By distribution channel, the targeted therapy segment accounted for the highest revenue-grossing segment in the global bone cancer treatment market in 2023 owing to the increasing prevalence of personalized medicine approaches, advancements in molecular profiling, and a growing understanding of specific molecular targets associated with various types of bone cancers. For instance, in December 2023, Amgen and Kyowa Kirin entered into an exclusive cooperation to develop and market AMG 751, a bispecific T-cell engager, for the treatment of multiple myeloma and other bone-related malignancies. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing digitalization of healthcare services, rising consumer preference for convenient and accessible pharmaceutical purchases, and advancements in e-commerce technologies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high healthcare expenditure, continuous advancements in medical research and technology, and a strong emphasis on early diagnosis and treatment. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of bone cancer, improving healthcare infrastructure, rising awareness about early cancer detection, and the implementation of supportive government initiatives. For instance, in December 2023, Bristol Myers Squibb received FDA orphan drug designation for BMY878 (PARP inhibitor), a medication used to treat Ewing sarcoma.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The market for bone cancer treatments is significantly driven by the disease's increasing global prevalence. The need for efficient treatment alternatives is projected to rise in tandem with the rise in the number of instances of bone cancer. Government programs that support the development of new drugs, clinical trials, and other forms of cancer research are vital. Increasing assistance can hasten the creation of novel treatments and enhance patient outcomes. For instance, in December 2023, the FDA approved Pfizer's Ibrance (palbociclib) to treat hormone-receptor-positive metastatic breast cancer that has spread to the bone.
By bone cancer type, the primary bone sarcoma segment accounted for the highest revenue-grossing segment in the global bone cancer treatment market in 2023 owing to the increasing incidence of primary bone sarcomas, advancements in targeted therapies specifically designed for this subtype, and a growing emphasis on personalized treatment approaches that address the unique characteristics of primary bone sarcomas. For instance, Novartis and Epizyme announced a collaboration in November 2023 to develop and market EZH2 inhibitors as a therapy for bone cancer. Additionally, the secondary bone cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of metastatic cancer cases, advancements in diagnostic techniques enabling early detection of secondary bone involvement, and the development of targeted therapies tailored to address the specific challenges associated with secondary bone cancer.
By treatment type, the surgery segment accounted for the highest revenue-grossing segment in the global bone cancer treatment market in 2023 owing to the increasing adoption of advanced surgical techniques, such as limb-salvage surgeries and minimally invasive procedures, which enhance treatment outcomes while preserving function. For instance, in December 2023, Eli Lilly presented preclinical results at the San Antonio Breast Cancer Symposium that indicated CYD2669 could play a role in reducing bone metastases in breast cancer. Additionally, the targeted therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing understanding of molecular pathways and genetic abnormalities associated with bone cancer, which has facilitated the development of more precise and effective targeted therapies.
By distribution channel, the targeted therapy segment accounted for the highest revenue-grossing segment in the global bone cancer treatment market in 2023 owing to the increasing prevalence of personalized medicine approaches, advancements in molecular profiling, and a growing understanding of specific molecular targets associated with various types of bone cancers. For instance, in December 2023, Amgen and Kyowa Kirin entered into an exclusive cooperation to develop and market AMG 751, a bispecific T-cell engager, for the treatment of multiple myeloma and other bone-related malignancies. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing digitalization of healthcare services, rising consumer preference for convenient and accessible pharmaceutical purchases, and advancements in e-commerce technologies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high healthcare expenditure, continuous advancements in medical research and technology, and a strong emphasis on early diagnosis and treatment. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of bone cancer, improving healthcare infrastructure, rising awareness about early cancer detection, and the implementation of supportive government initiatives. For instance, in December 2023, Bristol Myers Squibb received FDA orphan drug designation for BMY878 (PARP inhibitor), a medication used to treat Ewing sarcoma.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Bone Cancer Type, Treatment Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Bone Cancer Treatment Market Report 2023 - 2034
Bone Cancer Treatment Market Analysis & Forecast by Bone Cancer Type 2023 - 2034 (Revenue USD Bn)
- Primary Bone Cancer
- Osteosarcoma
- Chondrosarcoma
- Ewing Tumor
- Other Bone Cancer Types
- Secondary Bone Cancer
- Metastatic Bone Cancer
Bone Cancer Treatment Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Chemotherapy
- Doxorubicin
- Cisplatin
- Cyclophosphamide
- Etoposide
- Other Chemotherapies
- Targeted Therapy
- Denosumab
- Imatinib
- Radiation Therapy
- Surgery
- Other Treatments
Bone Cancer Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Online Pharmacies
Bone Cancer Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Bone Cancer Treatment Market: Bone Cancer Type Estimates & Trend Analysis
8. Bone Cancer Treatment Market: Treatment Type Estimates & Trend Analysis
9. Bone Cancer Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Bone Cancer Treatment Market
12. Europe Global Bone Cancer Treatment Market
13. Asia Pacific Global Bone Cancer Treatment Market
14. Latin America Global Bone Cancer Treatment Market
15. MEA Global Bone Cancer Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Novartis International AG
- Eli Lilly and Company
- Amgen Inc.
- Bayer AG
- Merck & Co. Inc.
- Sanofi
- Bristol Myers Squibb Company
- Roche Holdings AG
- Johnson & Johnson
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Celgene Corporation (acquired by Bristol Myers Squibb)
- Daiichi Sankyo Company Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.32 Billion |
| Forecasted Market Value ( USD | $ 2.19 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
